Issue Date: February 11, 2008
Albemarle Wins Anthera Contract
Albemarle has scored a contract to manufacture bulk quantities of varespladib, a cardiovascular disease drug from Anthera Pharmaceuticals that is in Phase III clinical trials. Scientists at Albemarle's South Haven, Mich., facility will optimize the production process and then manufacture the drug according to current Good Manufacturing Practices standards. Ontario-based Patheon will produce the finished tablet for the late-stage trials. Varespladib has shown promise in helping reduce inflammation and lower cholesterol levels in patients taking statin therapies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society